<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393701</url>
  </required_header>
  <id_info>
    <org_study_id>2020/007/HP</org_study_id>
    <nct_id>NCT04393701</nct_id>
  </id_info>
  <brief_title>A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry</brief_title>
  <acronym>LysoNeo</acronym>
  <official_title>A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include all newborns in Normandie region for 3 years (about 105,000 births)
      for whom signed consent by one (or two) parents will be collected. Based on our previous
      pilot study (2011) assessing MCAD and PKU using tandem mass spectrometry-based method in
      Normandie region in which informed consents have been signed for all newborns (43,000) but we
      are expecting a great willingness to participate to this project. Thus, we are aiming to
      include 100,000 newborns, and the study will be continued until we reach at least this
      target.

      The primary objective is to evaluate the epidemiology of MPS1 and Pompe disease using dried
      blood samples in the first cohort of neonates tested in France (Normandie region).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of newborns in relation to the number of cases of blotting paper collected</measure>
    <time_frame>From day 2 to day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of newborns with positive sample for Mucopolysaccharidosis type I</measure>
    <time_frame>From day 2 to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborns with positive sample for Pompe disease</measure>
    <time_frame>From day 2 to day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Neonatal Screening</condition>
  <condition>Lysosomal Storage Diseases</condition>
  <arm_group>
    <arm_group_label>neonates tested in Normandie, France</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All neonates will be tested in Normandie</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Additional blood sampling</intervention_name>
    <description>Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program</description>
    <arm_group_label>neonates tested in Normandie, France</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborn in a Normandy maternity hospital

          -  Newborn participating in the National Neonatal Screening Program

          -  Holder(s) of parental authority having read and understood the information letter and
             signed the informed consent form

        Exclusion Criteria:

        There are no criteria for non-inclusion in this study. Participation in the study, such as
        participation in the National Neonatal Screening Program, is not mandatory.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soumeya BEKRI, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soumeya BEKRI, Pr</last_name>
    <phone>+3323288</phone>
    <phone_ext>8990</phone_ext>
    <email>soumeya.bekri@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien BLOT</last_name>
    <phone>+3323288</phone>
    <phone_ext>8265</phone_ext>
    <email>julien.blot@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>David GUENET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Soumeya BEKRI</last_name>
      <phone>+3323288</phone>
      <phone_ext>8990</phone_ext>
      <email>soumeya.bekri@chu-rouen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

